Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1995 1
1996 2
1997 3
1998 1
1999 1
2000 3
2001 5
2002 8
2003 11
2004 12
2005 18
2006 13
2007 7
2008 11
2009 16
2010 25
2011 33
2012 25
2013 22
2014 32
2015 25
2016 38
2017 28
2018 24
2019 23
2020 32
2021 19
2022 26
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.
Altrichter S, Giménez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, Brooks L, Ho CN, Jain P, Lukka PB, Rodriguez-Suárez E, Walton C, Datto CJ; ARROYO Study Investigators. Altrichter S, et al. Br J Dermatol. 2024 Feb 17:ljae067. doi: 10.1093/bjd/ljae067. Online ahead of print. Br J Dermatol. 2024. PMID: 38367194
Performance of Three Large Language Models on Dermatology Board Examinations.
Mirza FN, Lim RK, Yumeen S, Wahood S, Zaidat B, Shah A, Tang OY, Kawaoka J, Seo SJ, DiMarco C, Muglia J, Goldbach HS, Wisco O, Qureshi AA, Libby TJ. Mirza FN, et al. Among authors: seo sj. J Invest Dermatol. 2024 Feb;144(2):398-400. doi: 10.1016/j.jid.2023.06.208. Epub 2023 Aug 2. J Invest Dermatol. 2024. PMID: 37541614 No abstract available.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
428 results